Novartis stock after-hours at EUR 126.65: plus 0.80 percent after the Xetra close
Published on 10/01/2026 at 17:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock was at EUR 126.65 after-hours at 5:47 p.m. CEST on October 1, 2026. That was up EUR 1.00, or plus 0.80 percent, versus the prior close of EUR 125.65 at Lang & Schwarz.
Trading in Frankfurt
The euro price was quoted after-hours at Lang & Schwarz following the Xetra session. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Novartis stock.
Cosentyx receives positive EU opinion
On September 18, 2026, Novartis Pharma AG said that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for Cosentyx in polymyalgia rheumatica. The recommendation covers adults who had an inadequate response to steroids or relapsed during steroid taper. The company said the opinion was supported by the Phase III REPLENISH trial, in which the primary and secondary endpoints were met across the 300-milligram and 150-milligram treatment arms.
HARBOR study misses primary endpoint
In a September 8, 2026 release, Novartis Pharma AG reported that the global Phase III HARBOR study of del-desiran in myotonic dystrophy type 1 did not show a statistically significant improvement versus placebo on its primary endpoint, video hand opening time. The company said it was evaluating the full dataset and maintained its 5% to 6% five-year sales compound annual growth guidance for 2025 through 2030.
